What oral progesterone dose is recommended for a woman with recurrent pregnancy loss?

Oral Progesterone Dosing for Recurrent Miscarriage

For women with recurrent pregnancy loss, oral micronized progesterone is NOT the preferred formulation—vaginal micronized progesterone 400 mg twice daily is the evidence-based recommendation, though oral dydrogesterone 10 mg twice daily represents an alternative oral option if vaginal administration is not feasible.

Primary Recommendation: Vaginal Route Preferred

The highest quality evidence demonstrates that vaginal micronized progesterone 400 mg twice daily is the most effective progestogen for women with recurrent miscarriage 1, 2. This is particularly important for women with:

• One or more previous miscarriages AND current early pregnancy bleeding (threatened miscarriage): vaginal progesterone increases live birth rate (RR 1.08,95% CI 1.02 to 1.15) 1
• Three or more previous losses: Number needed to treat = 8 2
• One or two previous losses: Number needed to treat = 20 2

The 2025 Canadian guideline explicitly recommends progesterone therapy, especially when started in the luteal phase 3.

If Oral Route Required: Dydrogesterone

When vaginal administration is not acceptable or feasible, oral dydrogesterone 10 mg twice daily is the evidence-based oral alternative 4, 5. In a randomized trial of 180 women with recurrent unexplained spontaneous abortion (mean 3.5 prior losses):

• Dydrogesterone reduced miscarriage rate to 13.4% versus 29% in controls (p ≤ 0.05) 4
• Treatment starts immediately upon pregnancy confirmation and continues until 12 weeks gestation
• Pregnancy salvage rate of 92% was achieved 5

Critical Caveat: Oral Micronized Progesterone Lacks Evidence

There is NO available data to assess the effectiveness of oral micronized progesterone for live birth outcomes in women with recurrent miscarriage 1. The FDA-approved oral progesterone capsules (200-400 mg daily) are indicated for secondary amenorrhea and endometrial protection during estrogen therapy 6—NOT for recurrent pregnancy loss.

While one study explored dosing relationships (100-400 mg daily based on BMI) 7, this was for menstrual disorders, not pregnancy outcomes. Another small trial comparing oral versus vaginal routes for threatened miscarriage showed oral 200 mg twice daily had better outcomes than vaginal 8, but this contradicts the larger, higher-quality Cochrane meta-analysis 1.

Important Clinical Pitfalls

1. Route matters: Do not assume oral and vaginal progesterone are interchangeable—the evidence strongly favors vaginal administration for pregnancy outcomes 1

2. Timing is critical: Progesterone should ideally be started in the luteal phase or immediately upon pregnancy confirmation, continuing through 12 weeks gestation 4, 3

3. Patient selection: The benefit is clearest for women with prior losses who develop early pregnancy bleeding, not necessarily for all women with recurrent loss 1

4. Safety profile: Both vaginal micronized progesterone and dydrogesterone show no increased risk of congenital abnormalities or significant adverse drug events 1

Practical Algorithm

Step 1: Confirm recurrent pregnancy loss (≥2 losses) 3

Step 2: If patient accepts vaginal administration → Vaginal micronized progesterone 400 mg twice daily

Step 3: If vaginal route refused/not feasible → Oral dydrogesterone 10 mg twice daily

Step 4: Start treatment in luteal phase or immediately upon positive pregnancy test

Step 5: Continue until 12 weeks gestation

Step 6: Provide trauma-informed care and close monitoring through early pregnancy assessment clinics 3

The evidence does NOT support using oral micronized progesterone capsules for this indication, despite their FDA approval for other gynecologic conditions 6, 1.